Figure 5 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression

Le résumé fourni par la source

Circulating GDF-15 levels correlated with disease aggressiveness in patients with EHE. A, Analysis of circulating cytokines in plasma samples of 16 patients with EHE and four healthy donors using the Human XL Cytokine Array showed higher GDF-15 levels in patients compared with healthy donors. B, GDF-15 levels, as detected by ELISA and expressed in pg/mL plasma, in patients with EHE compared with healthy donors in a training (retrospective; 8 higher-risk and 12 lower-risk patients and 32 healthy donors) and a testing (prospective; 6 higher-risk and 15 lower-risk patients and 32 healthy donors) cohort and in both the cohorts. C, Two clinical cases are reported showing levels of GDF-15 in a lower-risk patient (top) with stable disease at follow-up and a higher-risk patient (bottom) who had an initial tumor response and levels of GDF-15 reduced after being started on the mTOR inhibitor sirolimus followed by an increase in GDF-15 before the CT scan that showed disease progression. PD, progressive disease; SD, stable disease.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.